HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MAC and Milk for Fashion Week

This article was originally published in The Rose Sheet

Executive Summary

MAC Cosmetics will partner with photography and media organization Milk Studios to host a series of events for New York Fashion Week Sept. 10-17, firms say in July 23 release. The Estee Lauder Companies' brand and Milk will offer runway shows, presentations and special events with the participation of designers including Peter Som, Proenza Schouler, Alexander Wang and threeASFOUR. Partnership is fueled by the desire to "create a space where designers, makeup artists, hair stylists, photographers, media, retailers" and others can collaborate and create new ways of presenting fashion collections "in a unique environment, fostering the evolution of Fashion Week in New York," firms say. John Dempsey, group president of Estee Lauder, says MAC is a longtime supporter of New York Fashion Week and is proud to step up its advocacy. "We are delighted to help bring the vision of these talented designers to fruition," he said

You may also be interested in...



UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel